By

Ivonne
May 20, 2021ByIn

Op-ed: Time for civil society to take action to influence EU regulations on medicines for children and rare diseases

Continue Reading
May 20, 2021ByIn

Webinar: The revision of EU regulations on medicines for children and rare diseases 

Continue Reading
May 1, 2021ByIn

Civil society recommendations for improving the Orphan and Paediatric Regulations 

Joint_Recommendations_Paediatric_Orphan_Policy-dialogue_200521
Continue Reading
May 1, 2021ByIn

ECL’s contribution to the 2021 WHO Fair Pricing Forum 

2021-Fair-Pricing-Forum_ECL_contribution
Continue Reading
March 26, 2021ByIn

ECL welcomes the Council’s mandate to start negotiations on the HTA file

Continue Reading
March 21, 2021ByIn

ECL welcomes the Council’s agreement on a mandate to start negotiations on health technology assessments (HTA)

Continue Reading
February 11, 2021ByIn

European Commission’s accepts commitments by Aspen Pharmacare to cut prices for 6 critical cancer drugs

Continue Reading
December 1, 2020ByIn

Enabling informed decision-making about cancer screening participation

ECL_Second_Screening_Workshop_Dec_2020_final
Continue Reading
November 30, 2020ByIn

Webinar: Launch of the European Fair Pricing Network

Continue Reading
November 26, 2020ByIn

ECL welcomes Pharmaceutical Strategy’s ambitions to make medicines affordable and available for all patients

Continue Reading
1 … 6 7 8 9 10 … 13